NASDAQ:BLFS - BioLife Solutions Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.38
  • Forecasted Upside: 7.89 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.25 (0.54%)

This chart shows the closing price for BLFS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioLife Solutions Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLFS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLFS

Analyst Price Target is $50.38
▲ +7.89% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for BioLife Solutions in the last 3 months. The average price target is $50.38, with a high forecast of $61.00 and a low forecast of $33.00. The average price target represents a 7.89% upside from the last price of $46.69.

This chart shows the closing price for BLFS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in BioLife Solutions. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2021BenchmarkReiterated RatingBuy ➝ HoldMedium
5/14/2021BenchmarkDowngradeBuy ➝ HoldHigh
3/24/2021B. RileyBoost Price Target$35.50 ➝ $61.00Low
3/23/2021Maxim GroupBoost Price TargetBuy$40.00 ➝ $60.00High
3/23/2021StephensBoost Price TargetBuy ➝ Overweight$50.00 ➝ $55.00High
3/23/2021KeyCorpBoost Price TargetOverweight$40.00 ➝ $50.00High
3/23/2021BenchmarkUpgradeHold ➝ Buy$54.00High
3/18/2021B. RileyReiterated RatingBuyLow
12/28/2020Northland SecuritiesBoost Price Target$35.00 ➝ $55.00N/A
11/9/2020KeyCorpInitiated CoverageOverweight$40.00Low
10/19/2020B. RileyBoost Price Target$30.00 ➝ $35.00Low
9/23/2020B. RileyBoost Price Target$25.50 ➝ $30.00High
9/22/2020Maxim GroupBoost Price Target$26.00 ➝ $32.00High
9/22/2020Lake Street CapitalBoost Price TargetBuy$29.00 ➝ $35.00High
9/22/2020Northland SecuritiesBoost Price TargetOutperform$27.00 ➝ $35.00Medium
9/22/2020OppenheimerDowngradeOutperform ➝ Market PerformMedium
9/18/2020CowenInitiated CoverageOutperform$33.00High
8/11/2020BenchmarkDowngradeBuy ➝ Hold$21.00High
8/7/2020Maxim GroupInitiated CoverageBuy$26.00High
8/7/2020Northland SecuritiesReiterated RatingBuy$28.00Low
7/10/2020B. RileyBoost Price TargetBuy$20.00 ➝ $25.50Low
7/8/2020Maxim GroupBoost Price TargetBuy$18.00 ➝ $26.00Low
7/8/2020Northland SecuritiesReiterated RatingBuy$24.00 ➝ $28.00Low
6/4/2020HC WainwrightReiterated RatingBuy$17.00High
5/16/2020Maxim GroupReiterated RatingBuy$18.00High
5/15/2020StephensBoost Price TargetOverweight$23.00 ➝ $24.00High
5/6/2020OppenheimerReiterated RatingBuyHigh
5/5/2020HC WainwrightReiterated RatingBuy$17.00High
5/4/2020B. RileyLower Price TargetBuy$24.00 ➝ $22.00High
3/23/2020HC WainwrightLower Price TargetBuy$26.00 ➝ $17.00Medium
3/12/2020B. RileyLower Price TargetBuy$27.00 ➝ $24.00High
2/24/2020Lake Street CapitalInitiated CoverageBuy$25.00High
2/19/2020BenchmarkInitiated CoverageBuy$24.00High
2/6/2020B. RileyInitiated CoverageBuy$27.00High
1/7/2020StephensInitiated CoverageOverweight$23.00High
12/16/2019HC WainwrightReiterated RatingBuy$23.00 ➝ $26.00Low
11/20/2019OppenheimerInitiated CoverageOutperform$22.00High
9/17/2019Maxim GroupSet Price TargetBuy$26.00Low
9/4/2019Northland SecuritiesBoost Price TargetOutperform$18.00 ➝ $22.00High
8/9/2019Maxim GroupSet Price TargetBuy$24.00High
7/22/2019HC WainwrightInitiated CoverageBuy ➝ Buy$23.00High
7/9/2019Northland SecuritiesReiterated RatingBuy$18.00High
5/22/2019Maxim GroupSet Price TargetBuy$24.00Low
5/13/2019Northland SecuritiesReiterated RatingBuy$18.00Low
12/20/2018Janney Montgomery ScottUpgradeBuy$5.00Low
11/9/2018B. RileySet Price TargetBuy$22.00Low
10/3/2018B. RileySet Price TargetBuy ➝ Buy$22.00High
9/5/2018Maxim GroupReiterated RatingBuy$26.00High
8/14/2018B. RileySet Price TargetBuy$23.00Low
8/10/2018Northland SecuritiesReiterated RatingBuy$18.00Low
7/3/2018B. RileySet Price TargetBuy$19.00Low
6/7/2018B. RileyInitiated CoverageBuy$14.00Low
5/11/2018Maxim GroupBoost Price TargetBuy ➝ Buy$9.00 ➝ $12.00High
4/30/2018Maxim GroupSet Price TargetBuy$9.00Low
4/2/2018Maxim GroupReiterated RatingBuy$9.00High
3/19/2018Maxim GroupSet Price TargetBuy$8.00Low
3/12/2018Northland SecuritiesInitiated CoverageOutperformHigh
3/9/2018Maxim GroupSet Price TargetBuy$8.00High
1/4/2018Maxim GroupSet Price TargetBuy$8.00High
11/30/2017Maxim GroupUpgradeBuy$8.00Low
11/10/2017Maxim GroupBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.00N/A
10/26/2017Maxim GroupReiterated RatingBuy$7.00N/A
10/19/2017Maxim GroupSet Price TargetBuy$7.00N/A
9/19/2017Maxim GroupBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.00Low
8/11/2017Maxim GroupSet Price TargetBuy$6.00High
7/31/2017Maxim GroupReiterated RatingBuy$5.00Low
7/5/2017Maxim GroupReiterated RatingBuy$4.00High
7/5/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$2.62 ➝ $5.00High
6/14/2017Maxim GroupReiterated RatingBuy$4.00Low
5/13/2017Maxim GroupSet Price TargetBuy$4.00Medium
3/10/2017Maxim GroupReiterated RatingBuy ➝ Buy$3.00 ➝ $4.00High
1/19/2017Maxim GroupInitiated CoverageBuy$3.00N/A
9/13/2016Janney Montgomery ScottInitiated CoverageNeutral$2.10N/A
(Data available from 7/25/2016 forward)
BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $46.69
Low: $45.77
High: $46.89

50 Day Range

MA: $40.02
Low: $30.56
High: $48.55

52 Week Range

Now: $46.69
Low: $18.20
High: $49.47


52,519 shs

Average Volume

277,774 shs

Market Capitalization

$1.89 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of BioLife Solutions?

The following equities research analysts have issued research reports on BioLife Solutions in the last year: B. Riley, Benchmark Co., Cowen Inc, KeyCorp, Lake Street Capital, Maxim Group, Northland Securities, Oppenheimer Holdings Inc., Stephens, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for BLFS.

What is the current price target for BioLife Solutions?

8 Wall Street analysts have set twelve-month price targets for BioLife Solutions in the last year. Their average twelve-month price target is $50.38, suggesting a possible upside of 7.9%. B. Riley has the highest price target set, predicting BLFS will reach $61.00 in the next twelve months. Cowen Inc has the lowest price target set, forecasting a price of $33.00 for BioLife Solutions in the next year.
View the latest price targets for BLFS.

What is the current consensus analyst rating for BioLife Solutions?

BioLife Solutions currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLFS will outperform the market and that investors should add to their positions of BioLife Solutions.
View the latest ratings for BLFS.

What other companies compete with BioLife Solutions?

How do I contact BioLife Solutions' investor relations team?

BioLife Solutions' physical mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider's listed phone number is 425-402-1400 and its investor relations email address is [email protected] The official website for BioLife Solutions is